Akari Therapeutics (AKTX) Accumulated Expenses (2014 - 2026)

Akari Therapeutics has disclosed Accumulated Expenses across 13 years of filings, most recently posting $888000.0 for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $888000.0, up 25.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $888000.0 (up 25.07% YoY), and the FY2025 annual result was $2.3 million, up 395.14% from the prior year.
• Accumulated Expenses came in at $888000.0 for Q1 2026 at Akari Therapeutics, down from $2.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.1 million in Q4 2022 to a low of $50000.0 in Q2 2025.
• The 5-year median for Accumulated Expenses is $710000.0 (2025), against an average of $1.1 million.
• Peak annual rise in Accumulated Expenses reached 395.14% in 2025, while the deepest fall reached 89.08% in 2025.
• Akari Therapeutics' Accumulated Expenses stood at $3.1 million in 2022, then plunged by 50.25% to $1.6 million in 2023, then tumbled by 69.8% to $473000.0 in 2024, then soared by 395.14% to $2.3 million in 2025, then plunged by 62.08% to $888000.0 in 2026.
• The last three Accumulated Expenses figures came in at $888000.0 (Q1 2026), $2.3 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.